Emmaus Life Sciences

Emmaus Medical, based in Torrance, California, is a biopharmaceutical company focused on the discovery, development, and commercialization of treatments for rare and orphan diseases. The company’s primary product, Endari, is an oral pharmaceutical-grade L-glutamine powder designed to reduce acute complications of sickle cell disease in patients aged five and older. Emmaus Medical also offers NutreStore, an L-glutamine powder for short bowel syndrome, and is developing additional therapies, including a pharmaceutical-grade L-glutamine treatment for diverticulosis and products based on cell sheet technology for corneal diseases. The company has received FDA orphan drug designation and fast track designation for its sickle cell treatment, underscoring its commitment to addressing unmet medical needs in rare disease populations. Founded in 2000, Emmaus Medical continues to advance its clinical programs while exploring new therapeutic avenues.